Monday

MONDAY, 10 SEPTEMBER, 2007 (Concurrent Sessions WFN & IHA)

Hall 1, Hall 4 and Meeting Room 1

11:00-13:00

Scientific Session II: Pathogenesis and Pathophysiology of HD II

Chairs:

Lesley Jones (Cardiff, UK), Allan Tobin (New York, USA)

11:00

Proteolysis of Huntingtin
Michael Hayden (Vancouver, Canada)

11:25

Posttranslational Modifications of htt as Potential Therapeutic Target
Leslie M. Thompson (Irvine, USA)

11:50

Transcriptional Dysregulation in HD
Jang-Ho Cha (Boston, USA)

12:15

Neurodegeneration in Huntington’s Disease: Is Excitotoxicity Still Relevant?
Michael Levine (Los Angeles, USA)

12:40

Impaired Oxidative Phosphorylation in Huntington’s Disease: Diminished Glutamate Supply of Brain Mitochondria of HD Rats as one Mechanism for Mitochondriotoxic Action of htt51Q
Frank Gellerich (Magdeburg, Germany)

12:50

Huntington's Disease: Proteomics-Based Disease Hypothesis through Patho-pathway Construction
Eduardo Gonzalez-Couto (Siena, Italy)

Clinical Session II: Biomarkers in HD

Chairs:

Beth Borowsky (New York, USA), Jan Kassubek (Ulm, Germany)

11:00

DTI and Cortical Thickness as Surrogate Markers in HD
Diana Rosas (Charlestown, USA)

11:20

Brain Volumetric Change and Disease Progression in Huntington’s Disease
Andrea Ciarmiello (Naples, Italy)

11:30

Increased Caudate Atrophy Rates in Huntington’s Disease and Premanifest Subjects: a Novel Semiautomated Technique
Nicola Z. Hobbs (London, UK)

11:40

Striatal Atrophy in Huntington’s Disease is Leftward Biased
Adolf Weindl (Munich, Germany)

11:50

In Vivo Imaging of the Human Cerebral Cannabinoid-Type 1 Receptor in Huntington’s Disease
Wim Vandenberghe (Leuven, Belgium)

12:00

Dorsolateral Prefrontal Cortex Dysfunction in Presymptomatic Huntington’s Disease: Evidence from Event-Related fMRI
Robert Christian Wolf (Ulm, Germany)

12:10

Plasma 8-OH2-dG as a Diagnostic and Pharmacodynamic Biomarker for HD
Steven Hersch (Charlestown, USA)

12:25

Serum 8OHdG Levels in Manifest Huntington’s Disease and Healthy Controls Treated with Coenzyme Q10
Kevin M. Biglan (Rochester, USA)

12:35

Oculomotor Decision-Making as a Functional Biomarker in Huntington’s Disease
Matthieu Robert (London, UK)

12:45

Isolation, Characterisation and Quantification of Huntingtin Aggregates
Gillian Bates (London, UK)

IHA Session II

Chair:

Catherine Paradise (Dublin, Ireland)

11:00

How People with HD Think, how to Accommodate these Changes and how to More Efficiently Interact with those whom you Love (Part II)
James J. Pollard (Lowell, USA)

Back to Overview